Business, energy, technology, markets and global industry news from Business News Today

Lynk Pharmaceuticals

PharmaDeviceNews Lynk Pharmaceuticals
Lynk Pharmaceuticals completes patient enrollment in the Phase III zemprocitinib trial evaluating the oral JAK1 inhibitor for active ankylosing spondylitis. Representative image.
Pharma & Biotech

What the zemprocitinib enrollment milestone means for Lynk Pharmaceuticals’ late-stage pipeline

Lynk Pharmaceuticals completes Phase III zemprocitinib enrollment as ASAS40 efficacy, long-term safety and China filing tests move closer.

Read More
Representative image of a dermatology consultation and treatment planning, used to illustrate Lynk Pharmaceuticals’ zemprocitinib New Drug Application acceptance in China for moderate-to-severe atopic dermatitis.
Pharma & Biotech

Can zemprocitinib help Lynk Pharmaceuticals break into China’s crowded atopic dermatitis market?

Lynk Pharmaceuticals won NMPA acceptance for zemprocitinib in atopic dermatitis. Read what this filing changes, and what risks still remain.

Read More
Pharma & Biotech

What makes LNK01006 a potentially best-in-class TYK2 inhibitor with central immune impact?

Lynk Pharmaceuticals and Formation Bio have entered an exclusive licensing and development agreement for LNK01006, a next-generation, central nervous system (CNS)-penetrant TYK2 inhibitor. The deal gives Formation Bio global rights to the asset outside Greater China, with plans to initiate a Phase 1 clinical trial in the United States during the first half of 2026.

Read More